DJIA 16,563.30 -317.06 -1.88%
NASDAQ 4,369.77 -93.13 -2.09%
S&P 500 1,930.67 -39.40 -2.00%
market minute promo

Roche Holding Ltd. (ADR) (NASDAQOTH: RHHBY)

36.33 -0.50 (-1.36%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

RHHBY $36.33 -1.36%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $36.72
Previous Close $36.83
Daily Range $36.31 - $36.74
52-Week Range $30.48 - $38.71
Market Cap $204.2B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.5%)
Volume 597,006
Average Daily Volume 559,154
Current FY EPS $2.06

Sector

Healthcare

Industry

Pharmaceuticals

Roche Holding Ltd. (ADR) (RHHBY) Description

Website:

News & Commentary Rss Feed

Exelixis Sees Success in Melanoma Treatment With Drug Combination

Partnered with Roche-Genentech, Exelixis should be able to charge more than GlaxoSmithKline for its Melanoma treatment.

Novartis Vs. Everyone: Biologic Knockoffs

5 Pharmas Spending the Most to Develop Drugs: Merck, AstraZeneca, Roche, Bristol, and Lilly

Eli Lilly, Bristol-Myers Squibb, Roche, AstraZeneca, and Merck top the charts.

A Big Pharma Titan Prepares For the Next Generation

Roche looks to maintain leadership into a new generation of oncology.

Is Gilead About to Become an Oncology Powerhouse?

Gilead's (GILD) expanding oncology pipeline could give investors some exciting opportunities.

2 Health Care Partnerships Go Head-To-Head

While the partnership between GlaxoSmithKline (NYSE: GSK) and Ligand (NASDAQ: LGND) seems to be moving forward, the partnership between Roche (OTCMKTS: RHHBY) and PDL (NASDAQ: PDLI) has seemingly reached its end

AstraZeneca’s Alzheimer’s Drug Advances: Now What?

AstraZeneca reported disappointing fourth quarter revenues but showed progress with an Alzheimer's therapy the company has under development.

2 Deaths, 25% Plunge -- And Still A Big Upside

3 Ways Ariad Pharmaceuticals Can Salvage Iclusig

Iclusig has taken quite a few knocks since October, but there are three ways Ariad could rebuild the brand's value and boost shareholder value in the process.

Merck & Co., Inc. Shows Us How to Post Losses and Still Beat the Market

Here’s how to post a 28.6% profit loss, miss estimates, and still beat the S&P 500.

See More RHHBY News...

RHHBY's Top Competitors

RHHBY $36.33 (-1.36%)
Current stock: RHHBY
GSK $48.37 (-0.21%)
Current stock: GSK
JNJ $100.09 (-2.16%)
Current stock: JNJ
PFE $28.70 (-1.91%)
Current stock: PFE